NEONC TECHNOLOGIES HOLDINGS, INC. 8-K

What Happened NeOnc Technologies Holdings, Inc. announced on March 4, 2026 clinical data from the dose‑escalation portion of its Phase 1/2 trial for NEO212. The company issued a press release and hosted an investor conference call the same day to discuss the data; the 8‑K was filed March 6, 2026 and made the release, presentation, and call transcript publicly available.

Key Details

• Announcement date: March 4, 2026; Form 8‑K filed March 6, 2026.
• Subject: dose‑escalation portion of the Phase 1/2 clinical trial for NEO212.
• Investor materials furnished: press release, investor presentation, and conference call transcript.
• Disclosure made under Regulation FD (public release to all investors).

Why It Matters This filing signals NeOnc moving forward in early clinical development of NEO212 and publicly sharing trial data and management commentary with all investors. Retail investors should note the company is in the clinical-stage trial phase (not generating product revenue) and that the released materials may contain details relevant to upcoming development milestones, timelines, and potential next steps in the trial. Review the press release and conference materials for the full data and context before making investment decisions.